Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.2K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

592
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
592
Dementia01:30

Dementia

373
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
373

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selecting medical research data platforms for translational biomedical research: a five-tier overview and requirement-weighted assessment framework.

Frontiers in digital health·2026
Same author

Trends in Computational Metabolomics: A Perspective on Five Years of Software Development, Challenges, and Opportunities (2021-2025).

Analytical chemistry·2026
Same author

Screening for Alzheimer's disease in the community using an AI-driven screening platform: design of the PREDICTOM study.

The journal of prevention of Alzheimer's disease·2026
Same author

Whole blood gene expression moderates associations between AD biomarkers and cognitive decline in cognitively unimpaired older adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Elevated temporal tau PET predicts faster cognitive decline in women than men: A meta-analysis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Correction to "Natural Products Have Increased Rates of Clinical Trial Success throughout the Drug Development Process".

Journal of natural products·2026

Related Experiment Video

Updated: Nov 25, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.5K

Evaluating the Alzheimer's disease data landscape.

Colin Birkenbihl1,2, Yasamin Salimi1,2, Daniel Domingo-Fernándéz1,2

  • 1Department of Bioinformatics Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) Sankt Augustin Germany.

Alzheimer'S & Dementia (New York, N. Y.)
|December 21, 2020
PubMed
Summary

Evaluating Alzheimer's disease (AD) patient data reveals significant limitations. Direct analysis of real data is crucial for reproducible research, highlighting biases and data inconsistencies that hinder comparative studies.

Keywords:
Alzheimer's diseaseFAIR databiomarkerclinical studycohortcohort studydatadata accessdata setdata sharingdata viewerdata‐drivendementiadisease modelingmagnetic resonance imagingopen‐sciencepatient level data

More Related Videos

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

40.6K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

565

Related Experiment Videos

Last Updated: Nov 25, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.5K
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

40.6K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

565

Area of Science:

  • Neuroscience
  • Biomedical Informatics
  • Data Science

Background:

  • Numerous Alzheimer's disease (AD) cohort datasets exist.
  • Reproducible, data-driven research requires evaluating the current data landscape.

Purpose of the Study:

  • To directly investigate and evaluate nine patient-level AD cohort datasets.
  • To identify limitations in the AD data landscape for comparative analysis.

Main Methods:

  • Directly analyzed nine major clinical AD cohort studies' patient-level data.
  • Compared demographics, AD biomarker distributions, and data modalities.
  • Assessed ethnoracial diversity and availability of longitudinal data.

Main Results:

  • Significant differences found in cohort demographics and AD biomarker distributions.
  • Identified a strong bias towards White/Caucasian individuals in ethnoracial diversity.
  • Revealed critical limitations impeding cross-dataset comparative approaches.

Conclusions:

  • Direct investigation of patient-level data is imperative for a thorough assessment of the AD data landscape.
  • Metadata-based evaluations are insufficient for understanding data limitations.
  • Identified limitations hinder robust, comparative data-driven approaches in AD research.